Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyle T Helzer

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
NPJ Genomic Medicine|September 22, 2021
Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT SignaturesNicholas R Rydzewski, Erik Peterson, Joshua M Lang, et al.
JAMA Oncology|September 23, 2021
Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate CancerRahul Aggarwal, Nicholas R Rydzewski, Li Zhang, et al.
Communications Biology|March 14, 2024
A platform-independent AI tumor lineage and site (ATLAS) classifierNicholas R Rydzewski, Yue Shi, Chenxuan Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2023
Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate CancerJamie M Sperger, Kyle T Helzer, Charlotte N Stahlfeld, et al.
JCI Insight|September 24, 2024
Clinical cell-surface targets in metastatic and primary solid cancersMarina N Sharifi, Yue Shi, Matthew R Chrostek, et al.
Molecular Oncology|February 22, 2025
Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancerMarina N Sharifi, Eric Feng, Nicholas R Rydzewski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2022
Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell CarcinomaMatthew Bootsma, Rana R McKay, Hamid Emamekhoo, et al.
Nature Communications|October 14, 2025
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panelsKyle T Helzer, Marina N Sharifi, Jamie M Sperger, et al.
Nature Genetics|July 17, 2024
Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancerShuang G Zhao, Matthew Bootsma, Stanley Zhou, et al.
The Journal of Clinical Investigation|November 1, 2022
A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancerShuang G Zhao, Jamie M Sperger, Jennifer L Schehr, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
NPJ Genomic Medicine|September 22, 2021
Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT SignaturesNicholas R Rydzewski, Erik Peterson, Joshua M Lang, et al.
JAMA Oncology|September 23, 2021
Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate CancerRahul Aggarwal, Nicholas R Rydzewski, Li Zhang, et al.
Communications Biology|March 14, 2024
A platform-independent AI tumor lineage and site (ATLAS) classifierNicholas R Rydzewski, Yue Shi, Chenxuan Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2023
Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate CancerJamie M Sperger, Kyle T Helzer, Charlotte N Stahlfeld, et al.
JCI Insight|September 24, 2024
Clinical cell-surface targets in metastatic and primary solid cancersMarina N Sharifi, Yue Shi, Matthew R Chrostek, et al.
Molecular Oncology|February 22, 2025
Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancerMarina N Sharifi, Eric Feng, Nicholas R Rydzewski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2022
Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell CarcinomaMatthew Bootsma, Rana R McKay, Hamid Emamekhoo, et al.
Nature Communications|October 14, 2025
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panelsKyle T Helzer, Marina N Sharifi, Jamie M Sperger, et al.
Nature Genetics|July 17, 2024
Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancerShuang G Zhao, Matthew Bootsma, Stanley Zhou, et al.
The Journal of Clinical Investigation|November 1, 2022
A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancerShuang G Zhao, Jamie M Sperger, Jennifer L Schehr, et al.
Pageof 3